CN101563362B - 重组hcv e2糖蛋白 - Google Patents

重组hcv e2糖蛋白 Download PDF

Info

Publication number
CN101563362B
CN101563362B CN200780036968.8A CN200780036968A CN101563362B CN 101563362 B CN101563362 B CN 101563362B CN 200780036968 A CN200780036968 A CN 200780036968A CN 101563362 B CN101563362 B CN 101563362B
Authority
CN
China
Prior art keywords
hcv
glycoprotein
binding
protein
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200780036968.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN101563362A (zh
Inventor
K·麦克卡弗雷
H·卓莫
P·鲍伯里奥斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Original Assignee
Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2006904635A external-priority patent/AU2006904635A0/en
Application filed by Macfarlane Burnet Institute for Medical Research and Public Health Ltd filed Critical Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Publication of CN101563362A publication Critical patent/CN101563362A/zh
Application granted granted Critical
Publication of CN101563362B publication Critical patent/CN101563362B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109—Hepatitis C virus; Hepatitis G virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
CN200780036968.8A 2006-08-25 2007-08-24 重组hcv e2糖蛋白 Active CN101563362B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
AU2006904635A AU2006904635A0 (en) 2006-08-25 Recombinant E2 Envelope Glycoprotein for Improved Treatment of HCV virus
AU2006904635 2006-08-25
AU2006906090 2006-11-01
AU2006906090A AU2006906090A0 (en) 2006-11-01 Recombinant HCV E2 Glycoprotein for use in HCV Vaccine Treatment
AU2006906282 2006-11-10
AU2006906282A AU2006906282A0 (en) 2006-11-10 Recombinant HCV E2 Glycoprotein for use in HCV Vaccine Treatment
PCT/AU2007/001221 WO2008022401A1 (en) 2006-08-25 2007-08-24 Recombinant hcv e2 glycoprotein

Publications (2)

Publication Number Publication Date
CN101563362A CN101563362A (zh) 2009-10-21
CN101563362B true CN101563362B (zh) 2015-02-11

Family

ID=39106399

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200780036968.8A Active CN101563362B (zh) 2006-08-25 2007-08-24 重组hcv e2糖蛋白

Country Status (8)

Country Link
US (2) US8535686B2 (enExample)
EP (1) EP2061805B1 (enExample)
JP (2) JP5674310B2 (enExample)
KR (1) KR101500017B1 (enExample)
CN (1) CN101563362B (enExample)
AU (1) AU2007288129B2 (enExample)
CA (1) CA2661814A1 (enExample)
WO (1) WO2008022401A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5674310B2 (ja) * 2006-08-25 2015-02-25 ザ・マクファーレーン・バーネット・インスティテュート・フォー・メディカル・リサーチ・アンド・パブリック・ヘルス・リミテッド 組換えｈｃｖ ｅ２糖タンパク質
US20110091495A1 (en) * 2008-04-22 2011-04-21 Rutgers, The State University Of New Jersey Hcv e2 construct compositions and methods
US9758794B2 (en) 2008-04-22 2017-09-12 Rutgers, The State University Of New Jersey HCV E2 construct compositions and methods
US20110129498A1 (en) * 2008-06-03 2011-06-02 Okairos Ag Vaccine for the prevention and therapy of hcv infections
CA2658714A1 (en) * 2009-03-17 2010-09-17 Thomas Krey Hcv-derived polypeptides and uses thereof
CN102199613A (zh) 2010-03-25 2011-09-28 国立大学法人东京大学 感染性丙型肝炎病毒高生产hcv突变体及其应用
CN103354748B (zh) 2010-08-04 2016-09-28 麦克法兰博尼特医学健康研究公司 修饰的丙型肝炎病毒蛋白
KR20140036127A (ko) * 2010-11-26 2014-03-25 더 맥파레인 버넷 인스티튜트 포 메디칼 리서치 앤드 퍼블릭 헬스 리미티드 조성물 및 방법
US20130084301A1 (en) * 2011-08-30 2013-04-04 Steven Foung Cluster of Neutralizing Antibodies to Hepatitis C Virus
CN103102394B (zh) * 2013-02-27 2014-06-25 北京大学人民医院 丙型肝炎病毒b细胞表位肽puhi49及其应用
CN110049993A (zh) 2016-09-29 2019-07-23 麦克法兰布奈特医疗研究与公共健康研究所有限公司 组装的糖蛋白
CA3148840A1 (en) * 2019-07-26 2021-02-04 The Scripps Research Institute Engineered hcv e2 immunogens and related vaccine compositions
CN115843270A (zh) * 2020-05-11 2023-03-24 麦克法兰布奈特医疗研究与公共健康研究所有限公司 包括缺失可变结构域的e2多肽的丙型肝炎核酸疫苗
CN112730851B (zh) * 2021-03-31 2021-06-22 南京立顶医疗科技有限公司 一种高灵敏SARS-CoV-2中和抗体的检测方法、检测试剂盒

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1555415A (zh) * 2001-09-13 2004-12-15 XTL������ҩ���޹�˾ 合成的hcv包膜蛋白和它们用于接种的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0804584T3 (da) * 1994-10-21 2002-09-23 Innogenetics Nv Sekvenser af hepatitis C virus genotype 7 og deres anvendelse som profylaktiske, terapeutiske og diagnostiske midler
JP2002528140A (ja) * 1998-11-05 2002-09-03 ザ ボード オブ トラスティーズ オブ リーランド スタンフォード ジュニア ユニバーシティ ヒトｐａｎ−ｈｃｖヒトモノクローナル抗体
AU7602800A (en) 1999-09-23 2001-04-24 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof
US6682909B2 (en) * 2000-09-13 2004-01-27 Hawaii Biotech, Inc. Immunogenic composition of hepatitis C and methods of use thereof
EP1417298A2 (en) * 2001-04-24 2004-05-12 Innogenetics N.V. Core-glycosylated hcv envelope proteins
EP1716250B1 (en) * 2004-01-07 2015-08-05 Third Wave Technologies, Inc. Determination of hepatitis c virus genotype
JP5674310B2 (ja) * 2006-08-25 2015-02-25 ザ・マクファーレーン・バーネット・インスティテュート・フォー・メディカル・リサーチ・アンド・パブリック・ヘルス・リミテッド 組換えｈｃｖ ｅ２糖タンパク質

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1555415A (zh) * 2001-09-13 2004-12-15 XTL������ҩ���޹�˾ 合成的hcv包膜蛋白和它们用于接种的应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
RosaMaria Roccasecca,et al.Binding of the Hepatitis C Virus E2 Glycoprotein to CD81 Is Strain Specific and Is Modulated by a Complex Interplay between Hypervariable Regions 1 and 2.《JOURNAL OF VIROLOGY》.2003,第77卷(第3期),第1856–1867页. *
朱诗应 等.HCV 核心和截短的包膜蛋白E2 基因在昆虫细胞中的表达及其抗原性.《第二军医大学学报》.2004,第25卷(第9期),第962-965页. *

Also Published As

Publication number Publication date
KR101500017B1 (ko) 2015-03-09
JP5674310B2 (ja) 2015-02-25
JP5999524B2 (ja) 2016-09-28
US8535686B2 (en) 2013-09-17
US20140120127A1 (en) 2014-05-01
EP2061805B1 (en) 2020-02-12
EP2061805A4 (en) 2010-08-04
CA2661814A1 (en) 2008-02-28
KR20090053930A (ko) 2009-05-28
EP2061805A1 (en) 2009-05-27
AU2007288129A1 (en) 2008-02-28
WO2008022401A1 (en) 2008-02-28
US20110014209A1 (en) 2011-01-20
JP2010501594A (ja) 2010-01-21
CN101563362A (zh) 2009-10-21
US9598467B2 (en) 2017-03-21
AU2007288129B2 (en) 2013-03-07
JP2014240427A (ja) 2014-12-25

Similar Documents

Publication Publication Date Title
CN101563362B (zh) 重组hcv e2糖蛋白
JP2010501594A6 (ja) 組換えｈｃｖ ｅ２糖タンパク質
Alvarez‐Lajonchere et al. Immunogenicity of CIGB‐230, a therapeutic DNA vaccine preparation, in HCV‐chronically infected individuals in a Phase I clinical trial
Heile et al. Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: an endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-based vaccine candidates
CN102016026A (zh) 含有来自丙型肝炎病毒的嵌合基因的核酸
Krapchev et al. Recombinant Flag-tagged E1E2 glycoproteins from three hepatitis C virus genotypes are biologically functional and elicit cross-reactive neutralizing antibodies in mice
Fournillier et al. Expression of noncovalent hepatitis C virus envelope E1-E2 complexes is not required for the induction of antibodies with neutralizing properties following DNA immunization
CN1768078B (zh) 针对丙型肝炎病毒e1e2复合体的抗体、hcv颗粒的组合物和药物组合物
US9884109B2 (en) Compositions and methods
JP2020500837A (ja) アセンブルした糖タンパク質
Kachko et al. New neutralizing antibody epitopes in hepatitis C virus envelope glycoproteins are revealed by dissecting peptide recognition profiles
US11945842B2 (en) Tetravalent dengue vaccine
Torresi et al. A self‐adjuvanting multiepitope immunogen that induces a broadly cross‐reactive antibody to hepatitis C virus
Jiao et al. DNA immunization encoding the secreted nonstructural protein 3 (NS3) of hepatitis C virus and enhancing the Th1 type immune response
Xiang et al. Purification and application of bacterially expressed chimeric protein E1E2 of hepatitis C virus
US20030091590A1 (en) Recombinant rhabdoviruses as live-viral vaccines
Migliaccio et al. Evidence for a polytopic form of the E1 envelope glycoprotein of Hepatitis C virus
WO2002089728A2 (en) Recombinant rhabdoviruses as live-viral vaccines
Naik In vitro infectivity of the Hepatitis C Virus in the context of humoral immunity and immune escape
Vasiliauskaite Structural characterization of viral envelope glycoproteins
Walker Characterising viral evolution and the host humoral immune response in early primary HCV infection
Migliaccio core| E||| E2| p7|
Edwards Development of techniques for the isolation and characterisation of human monoclonal antibodies from Hepatitis C virus infected individuals

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant